American Heart Journal
Volume 141, Issue 6 , Pages 925-932 , June 2001

Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: A potential of hormone-guided treatment

Received 15 August 2000 ,Accepted 20 February 2001.

References 

  1. Mukoyama M, Nakao K, Hosoda K, et al.  Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402–1412
  2. Yasue H, Yoshimura M, Sumida H, et al.  Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203
  3. Yamamoto K, Burnett JCJ, Jougasaki M, et al.  Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–994
  4. Tsutamoto T, Wada A, Maeda K, et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  5. Richards AM, Nicholls MG, Yandle TG, et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921–1929
  6. Packer M, Bristow MR, Cohn JN, et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355
  7. CIBIS-II Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  8. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  9. Lechat P, Escolano S, Golmard JL, et al.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1997;96:2197–2205
  10. Kawai K, Takaoka H, Hata K, et al.  Prevalence, predictors, and prognosis of reversal of maladaptive remodeling in idiopathic dilated cardiomyopathy with intensive medical therapy. Am J Cardiol. 1999;84:671–676
  11. Troughton RW, Frampton CM, Yandle TG, et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  12. Tanaka M, Ishizaka Y, Ishiyama Y, et al.  Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertens Res. 1996;19:239–245
  13. Luchner A, Burnett JCJ, Jougasaki M, et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998;32:1839–1844
  14. Fujimura M, Yasumura Y, Ishida Y, et al.  Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 2000;6:3–10
  15. Richardson P, McKenna W, Bristow M, et al.  Report of 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842
  16. Sekiguchi M, Hiroe M, Morimoto S. On the standardization of histopathological diagnosis and semiquantitative assessment of the endo-myocardium obtained by endomyocardial biopsy. Bull Heart Inst Jpn. 1979;80(21):55–85
  17. Sahn DJ, Demaria A, Kisslo J, et al.  The committee on M mode standardization of the American Society of Echocardiography: recommendations regarding quantification in M mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  18. Teichholz LE, Kreulen T, Herman MV, et al.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7–11
  19. Devereux RB, Alonso DR, Lutas EM, et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  20. Shite J, Yokota Y, Yokoyama M. Heterogeneity and time course of improvement in cardiac function after cardioversion of chronic atrial fibrillation: assessment of serial echocardiographic indices. Br Heart J. 1993;70:154–159
  21. Goldstein DS, Feuerstein G, Izzo JLJ, et al.  Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 1981;28:467–475
  22. Murphy JM, Berwick DM, Weinstein MC, et al.  Performance of screening and diagnostic tests: application of receiver operating characteristic analysis. Arch Gen Psychiatry. 1987;44:550–555
  23. Luzier AB, Forrest A, Adelman M, et al.  Impact of angiotensinconverting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol. 1998;82:465–469
  24. Davis M, Espiner E, Richards G, et al.  Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440–444
  25. Motwani JG, McAlpine H, Kennedy N, et al.  Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993;341:1109–1113
  26. Choy AM, Darbar D, Lang CC, et al.  Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994;72:16–22
  27. Christensen G, Aksnes G, Ilebekk A, et al.  Release of atrial natriuretic factor during selective cardiac alpha- and beta-adrenergic stimulation, intracoronary Ca2+ infusion, and aortic constriction in pigs. Circ Res. 1991;68:638–644
  28. Yoshimoto T, Naruse M, Tanabe A, et al.  Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 1998;139:81–88
  29. Nakaoka H, Kitahara Y, Amano M, et al.  Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221–225
  30. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al.  Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499–1506
  31. Maeda K, Tsutamoto T, Wada A, et al.  Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825–832
  32. Yoshimoto T, Naruse M, Irie K, et al.  Beta-adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides. Eur J Pharmacol. 1998;351:61–66
  33. Sanderson JE, Chan WW, Hung YT, et al.  Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J. 1995;74:502–507
  34. Nakagawa O, Ogawa Y, Itoh H, et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280–1287
  35. Steimle AE, Stevenson LW, Fonarow GC, et al.  Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol. 1994;23:553–559
  36. Gilbert EM, Abraham WT, Olsen S, et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–2825
  37. Lowes BD, Gilbert EM, Lindenfeld JA, et al.  Differential effects of beta-blocking agents on adrenergic activity. Circulation. 2000;102(2 Suppl):II628–II629

☆ Reprint requests: Katsuya Hata, MD, PhD, FACC, First Department of Internal Medicine, Kobe University School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

PII: S0002-8703(01)86782-X

doi: 10.1067/mhj.2001.115435

American Heart Journal
Volume 141, Issue 6 , Pages 925-932 , June 2001

Article Tools

* Image Usage & Resolution